The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial.
To determine whether treatment with raloxifene has a beneficial effect on cognitive function in postmenopausal women, 50 postmenopausal women were randomized to receive raloxifene 60 mg, or placebo, for eight weeks. Participants completed pre- and post-treatment assessment of cognitive and psychological function including the Beck Anxiety and Beck Depression inventories, the SF-36 Scale of physical and emotional well-being, five tests of cognitive function including Block Design and Digit Span subtests of the Wechsler Adult Intelligence Scale-III (WAIS-III), the Logical Memory and Paired Associates subtests of the Wechsler Memory Scale-III, and the Digit Cancellation test. Results showed no significant effect attributable to eight weeks of treatment with raloxifene on cognitive, psychological, or health variables.
Haskell
Sally G
SG
Department of Medicine, Yale University School of Medicine, New Haven, USA. Sally.Haskell@Med.VA.Gov
Richardson
Emily D
ED
D000368:Aged; D003071:Cognition / Q000187:drug effects*; D005260:Female; D006306:Health Surveys; D006801:Humans; D007407:Interviews as Topic; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects* / Q000523:psychology; D020849:Raloxifene Hydrochloride / Q000494:pharmacology*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride